Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received approval from the human research ethics committee (HREC) to kick off its Phase I/II clinical trial assessing RECCE® 327 as a spray-on, broad-spectrum antibiotic therapy for mild skin and soft tissue diabetic foot infections (DFI).
The Phase I/II clinical trial is a single-centre, prospective, interventional study assessing the safety and efficacy of R327 as a broad-spectrum, topical anti-infective treatment for patients with mild skin and soft tissue DFI.
S & U PLC (LSE:SUS) should see “robust trends” continue into next year, according to analysts at Peel Hunt, who reiterated a ‘buy’ recommendation on the specialist lender.
The Peel Hunt analysts said the stock is not “adequately reflected” by its current share price and it, therefore, offers “attractive value.”
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) said drilling at the Havieron gold-copper project in Western Australia has continued to confirm and expand the high-grade extensions to known mineralisation in the Eastern Breccia and the Northern Breccia zones.
Work on the exploration decline reached 1,000 metres in November as an improvement in ground conditions helped moved the work back on schedule.
Pantheon Resources PLC's (AIM:PANR, OTC:PTHRF) Alaskan acreage could be host to as much as 17.8bn barrels of crude oil, that’s according to the latest reservoir modelling work from Schlumberger.
The company, in a statement, told investors that Schlumberger has now completed its Phase One reservoir modelling project which is described as “extremely detailed and comprehensive” – comprising six months (over 1,000 hours) of work by the industry-leading consultant.
Anglo Asian Mining PLC (AIM:AAZ, OTC:AGXKF) said drilling results at the Gilar deposit in Azerbaijan confirmed more than 60 metres of thick and continuous gold and copper mineralisation.
Drilling has demarcated six zones of mineralisation with the latest drilling defining a deeper zone of continuous mineralisation hosting significant gold, copper and zinc values, said the AIM-listed miner.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it dosed its first patient in a phase III trial for a new grass pollen vaccine, while screening is underway for a safety trial of its peanut allergy jab.
Grass MATA MPL, Allergy’s six-jab allergen-specific immunotherapy hay fever candidate, aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen, while VLP is a pioneering treatment for peanut and potentially other nut allergies.
S & U PLC (LSE:SUS) said trading is “very good” and that positive trends at its motor finance and property lending arms are expected to continue for at least the remainder of the financial year.
Highlighting the quality of its customer relationships and the receivables derived from them, the specialist lender said these receivables have this week risen to roughly a net £404mln from £370mln at the 31 July half-year point.
Metal Tiger PLC (AIM:MTR, OTC:MRTTF, ASX:MTR)has noted the appointment of Adam Wooldridge as chief executive 20% associate Cobre. Wooldridge is a founding partner of Kalahari Metals with over 25 years experience in Africa, the Middle East and Europe (read here).